Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia, Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy

  • Arguello-Tomas, Miguel|||0000-0002-3329-4151
  • Mozas, Pablo|||0000-0001-9528-4971
  • Albiol, Nil|||0000-0003-2942-1362
  • López-Esteban, Miguel
  • Sierra, Jorge|||0000-0002-7966-0356
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Martínez-Laperche, Carolina
  • Moga, Esther|||0000-0003-4264-6910
  • Piñeyroa, Juan A.
  • Delgado, Julio|||0000-0002-5157-4376
  • Osorio, Santiago
  • Moreno, Carol|||0000-0003-3275-0271
Background: Overall, the prognosis of patients with chronic lymphocytic leukemia (CLL) in the early phase of the disease (Rai 0, Binet A) is favorable; some patients never require therapy. However, some patients require intervention shortly after diagnosis. In the past decade, several risk scores (RS) have been developed to predict disease progression, yet some patients are misclassified. On the other hand, IGHV subset 2 (IGHV2) predicts poor outcomes. Methods: A retrospective and multicentric study was conducted to compare the accuracy of five different RS (IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno) to predict disease progression in 781 stage A previously untreated patients with CLL. As an exploratory analysis, it was further investigated whether the inclusion of the IGHV2 as a poor prognostic parameter improved the accuracy of RS. Results: All the scores identified a similar group of patients with CLL in early stage with low-, intermediate-, and high-risk progression. Discrimination was high and similar in all RS (c-index = 0.74-0.79, area under the curve = 0.7-0.75), as well as calibration (p =.98) and parsimony, although CLL-IPI showed the best results (Akaike information criterion = 441). A total of 34.4% of patients were categorized within the same RS and concordance was at least moderate between RS. Conclusion: Moreover, the results suggest that IGHV2 may improve the accuracy of RS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia

  • Arguello-Tomas, Miguel|||0000-0002-3329-4151
  • Lynton-Pons, Elionor|||0000-0001-5375-7195
  • Albiol, Nil|||0000-0003-2942-1362
  • López Ferrer, Anna|||0000-0002-2121-963X
  • Sierra, Jorge|||0000-0002-7966-0356
  • Moga, Esther|||0000-0003-4264-6910
  • Moreno, Carol|||0000-0003-3275-0271
Background: Autoimmune disorders (AIDs) are frequent in patients with chronic lymphocytic leukemia (CLL). There is little information on the clinical characteristics and pathogenesis of nonhematologic AIDs in patients with CLL, although both entities present immunologic alterations in their clinical onset. Methods: This single-center series included 907 patients with CLL who had a median follow-up of 6.6 years (range, 0.1-36.4 years). Results: In total, 156 patients developed an AID, including 99 patients (10.9%) with nonhematologic AIDs, 46 (5.1%) with autoimmune cytopenia (AIC), and 11 (1.2%) with both; autoimmune hypothyroidism and psoriasis were the most frequent AIDs. Patients with nonhematologic AIDs had low-risk genetic features and were related to a better time to first treatment than patients with AIC (13.8 vs. 5.5 years; p <.001). Patients with both CLL and psoriasis had the lowest risk of progression. The authors performed a T-cell/natural killer-cell and cytokine assessment among patients who had CLL with and without psoriasis. An unsupervised hierarchical clustering revealed a distinct cluster characterized by an expansion of T-helper 17 cells, T-regulatory cells, interleukin-17F, and interleukin-23. Conclusions: The current findings suggest that nonhematologic AIDs are prevalent in patients with CLL, and these patients have a better prognosis than patients who have AIC. The expansion of interleukin-17F-producing cells in patients with psoriasis may explain their good prognosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prognostic impact of circulating plasma cells in patients with multiple myeloma, implications for plasma cell leukemia definition

  • Granell, Miquel|||0000-0002-0366-3673
  • Calvo, Xavier|||0000-0001-7934-9130
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Martínez, Clara Mª
  • Teixidó, Montserrat
  • Gimenez, Mª Teresa
  • Senín, Alicia
  • Sanz, Patricia
  • Campoy, Desirée
  • Vicent, Ana
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Sierra, Jorge|||0000-0002-7966-0356
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Fernandez de Larrea Rodriguez, Carlos
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6-9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×10 9 /L vs. 214×10 9 /L, P <0.0001) and higher bone marrow plasma cells (median 53% vs. 36%, P =0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Conde, M. Isabel Prieto
  • Llop, Marta
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Prieto Conde, M. Isabel
  • Llop, Marta
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Montesinos, Pau|||0000-0002-3275-5593
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
In recent years, several attempts have been made to identify novel prognostic markers in patients with intermediate-risk acute myeloid leukemia (IR-AML), to implement risk-adapted strategies. The non-receptor tyrosine kinases are proteins involved in regulation of cell growth, adhesion, migration and apoptosis. They associate with metastatic dissemination in solid tumors and poor prognosis. However, their role in haematological malignancies has been scarcely studied. We hypothesized that PTK2/FAK, PTK2B/PYK2, LYN or SRC could be new prognostic markers in IR-AML. We assessed PTK2, PTK2B, LYN and SRC gene expression in a cohort of 324 patients, adults up to the age of 70, classified in the IR-AML cytogenetic group. Univariate and multivariate analyses showed that PTK2B, LYN and PTK2 gene expression are independent prognostic factors in IR-AML patients. PTK2B and LYN identify a patient subgroup with good prognosis within the cohort with non-favorable FLT3/NPM1 combined mutations. In contrast, PTK2 identifies a patient subgroup with poor prognosis within the worst prognosis cohort who display non-favorable FLT3/NPM1 combined mutations and underexpression of PTK2B or LYN. The combined use of these markers can refine the highly heterogeneous intermediate-risk subgroup of AML patients, and allow the development of risk-adapted post-remission chemotherapy protocols to improve their response to treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy

  • Alvarez-Fernández, Carmen|||0000-0003-0060-0447
  • Escribà Garcia, Laura|||0000-0002-3306-310X
  • Vidal, Silvia|||0000-0002-3909-6682
  • Sierra, Jorge|||0000-0002-7966-0356
  • Briones Meijide, Javier|||0000-0003-2750-3735
Immunotherapy based on the adoptive transfer of gene modified T cells is an emerging approach for the induction of tumor-specific immune responses. Memory stem T cells, due to their enhanced antitumor and self-renewal capacity, have become potential candidate for adoptive T cell therapy of cancer. Methods to generate memory stem T cells ex vivo rely on CD3/CD28 costimulation and the use of cytokines such as IL-7 and IL-15 during the entire culture period. However, a strong costimulation may induce differentiation of memory stem T cells to effector memory T cells. Here we show that manipulation of the length of the costimulation and addition of IL-21 enhance the ex vivo expansion of memory stem T cells. Purified naïve T cells from healthy donors were cultured in the presence of anti-CD3/CD28 coated beads, IL-7, IL-15 and/or IL-21 (25 ng/ml). T cells phenotype from the different memory and effector subpopulations were analyzed by multiparametric flow cytometry. A short anti-CD3/CD28 costimulation of naïve T cells, combined with IL-7 and IL-15 significantly increased the frequencies of CD4 + and CD8 + memory stem T cells ex vivo, compared to a prolonged costimulation (34.6 ± 4.4 % vs 15.6 ± 4.24 % in CD4 + ; p = 0.008, and 20.5 ± 4.00 % vs 7.7 ± 2.53 % in CD8 + ; p = 0.02). Moreover, the addition of IL-21 to this condition further enhanced the enrichment and expansion of CD4 + and CD8 + memory stem T cells with an increase in the absolute numbers (0.7 × 10 6 ± 0.1 vs 0.26 × 10 6 ± 0.1 cells for CD4 + ; p = 0.002 and 1.1 × 10 6 ± 0.1 vs 0.27 × 10 6 ± 0.1 cells for CD8 + ; p = 0.0002; short + IL-21 vs long). These new in vitro conditions increase the frequencies and expansion of memory stem T cells and may have relevant clinical implications for the generation of this memory T cell subset for adoptive cell therapy of patients with cancer. The online version of this article (doi:10.1186/s12967-016-0973-y) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication

FcγRIIb-BCR co-ligation inhibits B-cell receptor signaling in chronic lymphocytic leukemia

  • Bosch, Rosa|||0000-0002-7596-183X
  • Mora, Alba|||0000-0003-1064-8495
  • Cuellar, Carolina
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Gorlatov, Sergey
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Montserrat, Emili
  • Sierra, Jorge|||0000-0002-7966-0356
  • Rai, Kanti R.
  • Chiorazzi, Nicholas
  • Moreno, Carol|||0000-0003-3275-0271
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis

  • Moreno, María José
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Novelli, Silvana|||0000-0001-8750-0195
  • Mozos, Ana|||0000-0002-3350-1827
  • Aragó, Marc|||0000-0002-9645-0131
  • Pavón, Miguel Ángel|||0000-0003-3677-5329
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Pallarès, Victor|||0000-0002-9851-0345
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Blanco, Oscar
  • González-Díaz, Marcos
  • Malouf Sierra, Jorge|||0000-0001-5185-520X
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
The CXCR4/CXCL12 axis has been extensively associated with different types of cancer correlating with higher aggressiveness and metastasis. In diffuse large B-cell lymphoma (DLBCL), the expression of the chemokine receptor CXCR4 is involved in the dissemination of malignant B cells and is a marker of poor prognosis. CXCR7 is a chemokine receptor that binds to the same ligand as CXCR4 and regulates de CXCR4-CXCL12 axis. These findings together with the report of CXCR7 prognostic value in several tumor types, led us to evaluate the expression of CXCR7 in diffuse large B-cell lymphoma biopsies. Here, we describe that CXCR7 receptor is an independent prognostic factor that associates with good clinical outcome. Moreover, the expression of CXCR7 associates with increased survival in CXCR4 + but not in CXCR4- DLBCL patients. Thus, the combined immunohistochemical evaluation of both CXCR7 and CXCR4 expression in DLBCL biopsies may improve their prognostic value as single markers. Finally, we show that CXCR7 overexpression in vitro is able to diminish DLBCL cell survival and increase their sensitivity to antitumor drugs. Hence, further studies on the CXCR7 receptor may establish its role in DLBCL and the molecular mechanisms that modulate CXCR4 activity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia, Clinically Relevant Time Points and 100 Copies Threshold Value

  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Esquirol, Albert|||0000-0002-6062-5980
  • Carricondo, Maite
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Rubio, Miguel
  • Bussaglia, Elena|||0000-0002-9237-731X
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Estivill, Camino
  • Brunet, Salut|||0000-0003-0491-1672
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Malouf Sierra, Jorge|||0000-0001-5185-520X
The outcome of allogeneic hematopoietic stem cell transplantation (HCT) in patients with myeloid malignancies is better in those without minimal residual disease (MRD) than in those with MRD+, as assessed by multiparametric flow cytometry (MPFC). WT1 quantitation also has been used to assess the probability of relapse in acute myelogenous leukemia (AML) treated with chemotherapy. We analyzed the clinical value of normalized bone marrow WT1 levels as a measure of the expanded myeloid progenitor compartment in a consecutive series of 193 adult patients with myeloid malignancies who underwent HCT. Bone marrow WT1 levels before the HCT, at the first bone marrow aspirate after infusion, and in the follow-up samples after HCT were determined by means of real-time PCR using the European LeukemiaNet normalized method. We sought to clarify the prognostic relevance in terms of overall survival (OS), progression-free survival (PFS), and cumulative incidence of relapse (CIR). Based on earlier experience in AML, we selected a threshold of 100 copies, defining 2 groups: patients with <100 WT1 copies and those with ≥100 copies. Patients with <100 WT1 copies before HCT (median time, 36 days; range, 4 to 268 days) had a better OS, PFS, and CIR than those with ≥100 copies (40 ± 1 versus 29 ± 6 days, P =.004; 35 ± 9 versus 26 ± 6 days, P =.002; and 29 ± 7 versus 37 ± 6 days, P =.051). In the first bone marrow study after the HCT (median time, 42 days; range 14 to 157 days, respectively), patients with <100 WT1 copies also had better outcomes in terms of OS, PFS, and CIR (40 ± 7 versus 31 ± 9 days, P =.025; 36 ± 7 versus 30 ± 8 days, P =.004; and 29 ± 6 days versus 54 ± 9, P <.001, respectively). At this time point, bone marrrow samples with.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Do Patients and Physicians Agree When They Assess Quality of Life?

  • Barata, Anna|||0000-0003-0297-5920
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Gich, Ignasi|||0000-0003-3975-6588
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Barba, Pere|||0000-0001-7076-7969
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Brunet, Salut|||0000-0003-0491-1672
  • Esquirol, Albert|||0000-0002-6062-5980
  • García-Pallarols, Francesc
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Granell, Miquel|||0000-0002-0366-3673
  • Martinez, Jaume
  • Mensa, Irene
  • Novelli, Silvana|||0000-0001-8750-0195
  • Sánchez González, Blanca
  • Valcárcel, David|||0000-0002-8747-078X
  • Malouf Sierra, Jorge|||0000-0001-5185-520X
Patient and physician agreement on the most significant symptoms is associated with treatment outcomes and satisfaction with care. Thus, we sought to assess patient and physician agreement on patient-reported quality of life (QoL), and whether patient-related variables predict disagreement. In this cross-sectional, multisite study, patients and physicians completed the FACT-BMT at day 90. Agreement was analyzed with the intraclass coefficient correlation (ICC). Rates of underestimation and overestimation were calculated. Logistic regression models identified predictors of disagreement. We analyzed 96 pairs of questionnaires completed by 96 patients and 11 physicians. The patients' median age was 54 years, 52% were men, and 52% had undergone allogeneic hematopoietic cell transplantation (HCT). The physicians' median age was 42, 64% were men, and they had worked in the HCT field for an average of 12 years. Agreement on QoL was moderate (ICC = .436). Exploratory analyses revealed poor agreement for emotional (ICC = .092) and social (ICC = .270) well-being and moderate agreement for physical (ICC = .457), functional (ICC = .451), and BMT concerns (ICC = .445). Patients' well-being was underestimated by physicians in 41% to 59% of the categories of well-being parameters, and overestimated in 10% to 24%. Patient's anxiety predicted less disagreement in all scales except in social well-being, for which nonsignificant associations were observed. Patient-related variables explained 12% to 19% of the variance in disagreement across well-being scales. Patient and physician agreement on QoL was suboptimal, particularly in emotional and social well-being. The implementation of patient-reported outcomes in the daily care of HCT recipients may contribute to improving patient-centered care.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation

  • Barba, Pere|||0000-0001-7076-7969
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Pérez-Simón, José Antonio|||0000-0003-3616-6101
  • Fernandez Aviles, Francesc|||0000-0003-3051-3926
  • Castillo Flores, Nerea
  • Piñana, José Luis|||0000-0001-8533-2562
  • López-Anglada, Lucía|||0000-0003-1727-8546
  • Rovira Argelagués, Montserrat|||0000-0001-7786-9079
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Carreras, Enric|||0000-0002-3134-9964
  • López Corral, Lucia|||0000-0003-1908-5596
  • Sierra, Jorge|||0000-0002-7966-0356
  • Valcárcel, David|||0000-0002-8747-078X
This study was conducted to determine whether the integration of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) and the European Group for Blood and Marrow Transplantation (EBMT) score would improve individual capacity for stratification of high-risk HCT candidates. A total of 442 consecutive patients receiving an allogeneic HCT after reduced-toxicity conditioning was included. Final HCT-CI and EBMT scores were calculated and validated. Then, patients were grouped into a 6-category new combination model according to the HCT-CI (0, 1 to 2, ≥3) and EBMT scores (0 to 3, 4 to 7), and the model's predictive capacity was also evaluated. Median HCT-CI and EBMT scores were 3 and 4, respectively. Increased HCT-CI was associated with higher 4-year nonrelapse mortality (NRM) and lower 4-year overall survival (OS), whereas a high EBMT score was associated with higher 4-year NRM. The HCT-CI showed a trend for a better predictive capacity than the EBMT score (c-statistic.6 versus.54, P=1). According to the new model, patients within HCT-CI of 0 and HCT-CI of 1 to 2 groups had similar risk of NRM independently of their EBMT score. Within the HCT-CI ≥ 3 group, patients with low EBMT score showed lower NRM (25% versus 40%, P=04) and a trend to higher OS (52% versus 36%, P=06) than patients with a high EBMT score. Moreover, patients with HCT-CI ≥ 3 and EBMT score 0 to 3 had similar outcomes than those with HCT-CI of 1 to 2. In conclusion, the combination of HCT-CI and the EBMT score is feasible and might contribute to a better identification of high-risk patients, improving selection of best allogeneic HCT candidates. © 2014 American Society for Blood and Marrow Transplantation.